DNA methylation is an epigenetic modification where a chemical group (methyl) is added to cytosine nucleotides in the genome. In normal cells, this modification helps control which genes are active and which are silenced. In cancer, this pattern is broadly disrupted.
Cancer researchers have long focused on hypermethylation - the inappropriate silencing of tumor suppressor genes through excessive methylation at their promoters. This mechanism is well-studied and is the basis for several epigenetic cancer therapies. However, the opposite change, hypomethylation (loss of methylation), has received far less attention despite being equally common in cancer.
This study uses B cell chronic lymphocytic leukemia (B-CLL) as a model system because it has particularly prominent global hypomethylation as a characteristic feature. By analyzing matched methylation and gene expression data from 30 CLL patients compared to healthy B cells, the researchers aimed to clarify the biological role of hypomethylation in cancer development.
The researchers analyzed genome-wide DNA methylation data from 30 CLL patient samples compared to three normal CD19+ B cell control samples using reduced representation bisulfite sequencing (RRBS). This approach captures methylation at CpG-rich regions throughout the genome at single-base resolution.
To identify the most biologically significant changes, the team focused on consistent differentially methylated regions (C-DMRs) - genomic regions that showed the same methylation change (hyper or hypo) in the majority of CLL patients. Using a binomial statistical test, they identified 658 consistent hypomethylated regions and 982 consistent hypermethylated regions common across patients despite clinical heterogeneity.
Two permutation tests confirmed these C-DMRs were not due to chance: one permuted sample labels and one permuted methylation values across genomic regions. Both showed that the observed C-DMR patterns were highly statistically significant, establishing that consistent methylation changes exist across CLL patients even though individual patients vary greatly in their clinical presentation.
The genomic locations of hyper- and hypomethylated regions were strikingly different. Hypermethylated regions clustered at gene promoters (64%) and 5'UTRs (43%), consistent with their known role in silencing gene transcription by blocking transcription factor access to gene start sites.
Hypomethylated regions, in contrast, were predominantly found in introns (36%), 3'UTRs (29%), and intergenic regions (24%). Only 15% of hypomethylated regions overlapped with CpG islands, while 97% of hypermethylated regions did. This distinct genomic distribution suggests hypomethylation operates through fundamentally different mechanisms than hypermethylation.
Hypomethylated regions also overlapped strongly with enhancer elements - regulatory sequences that boost gene activity from a distance. This enhancer enrichment suggests that hypomethylation may activate oncogenes not by altering their promoters directly but by activating distal regulatory elements that increase transcription of cancer-promoting genes.
Pathway enrichment analysis revealed that genes overlapping with hypomethylated regions were enriched for the B cell receptor (BCR) signaling pathway and the p53 signaling pathway - both central to CLL biology. BCR signaling is a known driver of CLL survival and proliferation, making its association with hypomethylation highly relevant to disease mechanism.
Gene ontology analysis of hypomethylated regions identified enrichment for biological processes including chromatin modification, transcription regulation, programmed cell death, and leukocyte activation. In stark contrast, hypermethylated regions were enriched for the opposite processes: positive regulation of transcription and cell differentiation - processes that are being suppressed in CLL.
The transcription factor binding site analysis linked hypomethylated regions to factors critical for B cell development, including EBF1, RUNX3, TCF3, PU.1, and PAX5. EBF1 in particular is a master regulator of B cell identity, and its enrichment at hypomethylated sites suggests that hypomethylation may activate or maintain inappropriate B cell programs that sustain CLL growth.
To understand the regulatory context of methylation changes, the researchers systematically tested which histone modifications and chromatin states were associated with hypo- versus hypermethylated regions using ENCODE project data. The results revealed a clear bimodal pattern.
Hypomethylated regions were strongly enriched for activating histone marks: H3K4me1, H3K27ac, and H3K79me2. These marks collectively indicate regions of active enhancer activity and transcriptional elongation. In contrast, hypermethylated regions were enriched for H3K27me3, a mark of polycomb-mediated repression associated with the EZH2 methyltransferase.
At the level of chromatin state annotations, hypomethylated regions were enriched in strong and weak enhancer states, while hypermethylated regions clustered in repressed and poised promoter states. This chromatin state analysis confirms that hypomethylation and hypermethylation are operating on distinct functional genomic compartments with opposing roles in gene regulation.
The study found an unusual pattern in 3'UTR methylation: unlike promoter methylation, which negatively correlates with gene expression, methylation within 3'UTR exons showed a weak but positive correlation with gene expression. This is a departure from the standard model of methylation silencing transcription.
To systematically explore this relationship, the team used weighted gene correlation network analysis (WGCNA) on matched expression and 3'UTR methylation data from 19 CLL samples, identifying co-expression modules and co-methylation modules enriched for cancer-related biological processes.
The most significantly preserved modules between expression and 3'UTR methylation data were enriched for signaling, apoptosis, and cell proliferation - processes central to cancer development. This network-level analysis demonstrates that 3'UTR methylation changes in CLL are not random but are functionally coordinated with gene expression changes in biologically meaningful ways.
A central finding of the paper is that hypo- and hypermethylation do not act independently - they are functionally coordinated to drive cancer development in a complementary fashion. While hypermethylation blocks cell cycle exit and differentiation, hypomethylation simultaneously promotes growth, proliferation, and survival signaling.
A concrete example of this coordination: the FOS gene (involved in cell-cycle exit) is hypermethylated and repressed, while CyclinD1 (driving the G1-S cell cycle transition) is hypomethylated and active. Similarly, anti-apoptotic genes like BCL2 are hypomethylated and overexpressed, while PTEN (a tumor suppressor) is hypermethylated and silenced. These paired changes push the cell simultaneously toward division and away from death.
Key specific genes identified as hypomethylated and functionally implicated in CLL progression include BCL2, CCND1, LYN, BCL3, EBF1, EGFR, and ERBB2. Many of these are established oncogenes, and their hypomethylation provides a new regulatory explanation for their overexpression in CLL beyond previously described genetic or transcriptional mechanisms.
This study directly challenges the view that hypomethylation in cancer is a passive, random consequence of global genomic instability. The existence of consistent, non-random hypomethylated regions across 30 CLL patients - enriched in biologically meaningful pathways and regulatory elements - demonstrates that hypomethylation is a targeted, active contributor to cancer progression.
The dual role of methylation in cancer - with hypermethylation silencing tumor suppressors and hypomethylation activating oncogenes - means that epigenetic therapies targeting only one arm of this system may be insufficient. Understanding both processes together may be necessary to design effective epigenetic interventions in CLL and other cancers.
Future work should investigate whether the specific hypomethylated regions identified here could serve as biomarkers for CLL diagnosis, prognosis, or treatment response. The finding that consistent hypomethylation patterns exist across patients despite clinical heterogeneity suggests they may capture fundamental aspects of CLL biology that transcend individual variation.